InvestSMART

Nyrada Inc (ASX:NYR)

ALERT: Price-sensitive ASX Announcement for NYR
Current share price for NYR : $0.520 -0.035 (-6.31%)+
Announcement
Release
20 May 2026 9:13AM
Price at Release
$0.555
Full Release
download
Summary
Nyrada Inc, an Australian biotechnology company, announced the promising preclinical results of their lead drug candidate, Xolatryp®, which enhances the anti-tumor efficacy of anthracycline chemotherapy specifically in liver cancer models. The study demonstrated that Xolatryp, when used in conjunction with doxorubicin, a common chemotherapy drug, resulted in a significant reduction in tumor volume and showed promise as both a monotherapy and combination therapy. The results support the potential of Xolatryp to improve therapeutic outcomes for cancer patients treated with anthracycline drugs. Additionally, a provisional patent application has been lodged to protect Xolatryp as an anti-cancer agent, complementing an earlier patent for its composition. Nyrada focuses on developing therapies targeting TRPC ion channels, with ongoing studies aimed at further evaluating Xolatryp's efficacy and safety.
Key Points
  • Xolatryp enhances doxorubicin's anti-tumor effect in liver cancer models.
  • Xolatryp shows anti-tumor activity both as monotherapy and in combination.
  • The combination reduced tumor volume by 57% compared to control at Day 14.
  • Xolatryp's monotherapy resulted in a 32% reduction in tumor volume.
  • Future studies aim to optimize dosing strategies for better efficacy.
  • Potential for Xolatryp to improve outcomes in anthracycline-treated cancer.
  • Provisional patent application lodged for Xolatryp as an anti-cancer agent.
  • Nyrada focuses on TRPC ion channel inhibitors for multiple medical conditions.
  • Nyrada continues to evaluate Xolatryp across various tumor types.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.